A 30 YEAR JOURNEY
WITH A RELENTLESS
FOCUS ON SCIENCE

George D. Yancopoulos, MD, PhD, a highly regarded young molecular immunologist at Columbia University, launches Regeneron

Science publishes our first paper, which becomes the most highly cited neurobiology paper of the year

We announce a collaboration to develop neurotrophic factors

REGN stock begins trading publicly on the NASDAQ; the Initial Public Offering raises $91.6 million

Clinical development of our first investigational drug, a neurotrophic factor, begins

We acquire space for a drug manufacturing facility in Rensselaer, NY, years before having an FDA-approved product

Industry legend P. Roy Vagelos, MD, becomes Chairman of the Board, a position he still holds today

Dr. Vagelos, another businessman-scientist who had previously led Merck's R&D division, encourages us to focus our research on disease settings where the biological profile can be fully characterized and the clinical benefit evaluated more quickly

The Phase 3 trial of our first neurotrophic factor does not achieve its primary endpoint, and though the team is disappointed, we regroup to focus on new therapeutic solutions

George Yancopoulos, MD, PhD, becomes the decade's 11^th most highly cited scientist in the world

ARCALYST^? (rilonacept) Injection, our first Trap technology, begins clinical exploration

Our first paper on VelociGene^? is published, introducing the world to our proprietary Veloci technologies

We become one of the original sponsors of the Westchester Science & Engineering Fair (WESEF) to support and reward scientific excellence in promising high school students

EYLEA^? (aflibercept) Injection begins clinical development

A collaboration with Bayer HealthCare focuses on developing EYLEA^? (aflibercept) Injection outside the U.S.

Sarilumab, our first fully human antibody, enters clinical development

A collaboration with Sanofi focuses on developing fully human antibodies using our VelocImmune^? technology platform

The FDA approves our first medicine, ARCALYST^? (rilonacept) Injection

We expand and extend our antibody collaboration with Sanofi

PRALUENT^? (alirocumab) Injection begins clinical development

We hire our 1,000^th employee and move into new buildings on our Tarrytown campus

We begin sponsorship of the BioBus, a mobile laboratory, to drive hands-on science education in underserved school districts

The FDA approves EYLEA^? (aflibercept) Injection for its first indication

Our President and CEO, Leonard S. Schleifer, is named Ernst & Young's 2011 New York Entrepreneur Of The Year^?

The Science Top Employer survey names us the #1 employer in the global biopharmaceutical industry

Scrip Intelligence names us Biotech Company of the Year

We announce the first recipients of our annual Regeneron Prize for Creative Innovation

Our European business office opens in Dublin, Ireland

Scrip Intelligence names Len and George as the "Management Team of the Year"

The Regeneron Genetics Center, a new human genetics initiative, officially launches

The FDA grants investigational antibody dupilumab Breakthrough Therapy designation

We initiate the STEM Teaching Fellowship, a joint effort with the STEM Leadership Center, to develop a highly trained science teacher community, and Sci2Med Academy in collaboration with Yonkers Partners in Education to broaden career horizons for students who are underrepresented in the science fields

We begin building our first ex-U.S. IOPS site in Limerick, Ireland

The FDA approves PRALUENT^? (alirocumab) Injection, our fourth FDA-approved medicine and first FDA-approved fully human monoclonal antibody

We launch a major new immuno-oncology collaboration with Sanofi

We enter into an agreement with the U.S. government for the development of a new antibody treatment for the Ebola virus

We are named as the new title sponsor for the Science Talent Search (just the third in the prestigious competition's 75-year history)

The FDA approves DUPIXENT^? (dupilumab) Injection, our fifth FDA-approved medicine

FDA approves KEVZARA^? (sarilumab) Injection, our sixth FDA-approved medicine and second fully human monoclonal antibody

Recognized on the Civic 50 list of most community-minded companies in the United States

2018 marks the thirtieth anniversary of Regeneron’s founding

FDA approves Libtayo^? (cemiplimab-rwlc) Injection, our seventh FDA-approved medicine

The FDA approves a new indication for DUPIXENT^? (dupilumab) Injection

Regeneron debuts on the prestigious Dow Jones Sustainability World Index of Most Sustainable Companies; also included as one of Forbes’ “Most JUST Companies,” Newsweek’s “Most Responsible Companies” and the Civic 50 list of most-community minded companies in the U.S.

The PALM clinical trial for Ebola patients in the Democratic Republic of Congo is stopped early after our investigational medicine shows superiority to the previous standard of care.

The FDA and European Commission approves new indications for EYLEA? (aflibercept) injection, DUPIXENT? (dupilumab) injection, Libtayo? (cemiplimab) injection and Praluent? (alirocumab) injection.

Regeneron and Cold Spring Harbor Laboratory unveil new dedicated laboratories for student science education.

Society for Science & the Public announces Regeneron as new sponsor of the International Science and Engineering Fair.